Blog

The latest thoughts from Medicines Law & Policy partners.

WIPO and pharma industry launch global medicines patent database

On 25 September, the World Intellectual Property Organisation (WIPO) in collaboration with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launched the Patent...

TRIPS Council to discuss IP and the public interest in the context of Covid-19

The search for new treatments and vaccines needed to respond to the Covid-19 outbreak has laid bare some key issues around intellectual property (IP)...

The European Commission’s compulsory licensing proposals are sensible but do not go far enough

An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...

Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...

Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...

Drug Price Transparency Calls Move from South Africa to World Health Assembly

by Katrina Perehudoff and Jennifer Sellin Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...

Medicines Law & Policy Intervention at the WHO Pandemic Accord Negotiations

This statement was delivered on 19 February at the World Health Organization in Geneva, on the occasion of the 8th Intergovernmental Negotiating Body to...